{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:11:31Z","timestamp":1791583891844,"version":"4.3.4"},"reference-count":198,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013091","name":"Science and Technology Major Project of Guangxi","doi-asserted-by":"publisher","award":["AA24011004"],"award-info":[{"award-number":["AA24011004"]}],"id":[{"id":"10.13039\/501100013091","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017691","name":"Guangxi Key Research and Development Program","doi-asserted-by":"publisher","award":["AB23026058"],"award-info":[{"award-number":["AB23026058"]}],"id":[{"id":"10.13039\/501100017691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019534","name":"Science Fund for Distinguished Young Scholars of Guangxi Province","doi-asserted-by":"publisher","award":["2022GXNSFFA035026"],"award-info":[{"award-number":["2022GXNSFFA035026"]}],"id":[{"id":"10.13039\/501100019534","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.bbrc.2025.153155","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T17:01:03Z","timestamp":1766163663000},"page":"153155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Targeting strategies, clinical translation and translational barriers of liposomes in cancer therapy"],"prefix":"10.1016","volume":"796","author":[{"given":"Jingyi","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingtong","family":"Na","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honghua","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2025.153155_bib1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bbrc.2025.153155_bib2","first-page":"2","article-title":"Highlights of recent cancer research. Holist. Integr","volume":"1","author":"Dong","year":"2022","journal-title":"Oncol"},{"key":"10.1016\/j.bbrc.2025.153155_bib3","first-page":"11","article-title":"Cancer-triggered systemic disease and therapeutic targets. Holist. Integr","volume":"3","author":"Cao","year":"2024","journal-title":"Oncol"},{"key":"10.1016\/j.bbrc.2025.153155_bib4","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41392-023-01462-z","article-title":"Radiation-induced tumor immune microenvironments and potential targets for combination therapy","volume":"8","author":"Guo","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.bbrc.2025.153155_bib5","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.semcancer.2020.01.011","article-title":"Targeting cancer cells with nanotherapeutics and nanodiagnostics: current status and future perspectives","volume":"69","author":"Ali","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bbrc.2025.153155_bib6","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.semcancer.2019.11.002","article-title":"Specific targeting cancer cells with nanoparticles and drug delivery in cancer therapy","volume":"69","author":"Raj","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bbrc.2025.153155_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.cis.2023.102930","article-title":"Advanced liposome and polymersome-based drug delivery systems: considerations for physicochemical properties, targeting strategies and stimuli-sensitive approaches","volume":"317","author":"Kans\u0131z","year":"2023","journal-title":"Adv. Colloid Interface Sci."},{"key":"10.1016\/j.bbrc.2025.153155_bib8","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jconrel.2025.01.047","article-title":"Targeting antibodies dissociate from drug delivery liposomes during blood circulation","volume":"379","author":"Bj\u00f6rgvinsd\u00f3ttir","year":"2025","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.bbrc.2025.153155_bib9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jconrel.2020.01.009","article-title":"Magnetic iron oxide nanoparticles for imaging, targeting and treatment of primary and metastatic tumors of the brain","volume":"320","author":"Israel","year":"2020","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.bbrc.2025.153155_bib10","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jconrel.2021.05.032","article-title":"Solid lipid nanoparticles for hydrophilic drugs","volume":"335","author":"Mirchandani","year":"2021","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.bbrc.2025.153155_bib11","doi-asserted-by":"crossref","first-page":"16982","DOI":"10.1021\/acsnano.1c04996","article-title":"Lipid nanoparticles\u2500from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement","volume":"15","author":"Tenchov","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.bbrc.2025.153155_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202304006","article-title":"Research status of dendrimer micelles in tumor therapy for drug delivery","volume":"19","author":"Wang","year":"2023","journal-title":"Small"},{"key":"10.1016\/j.bbrc.2025.153155_bib13","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/2081295a0","article-title":"Cation permeability of phospholipid model membranes: effect of narcotics","volume":"208","author":"Bangham","year":"1965","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2025.153155_bib14","first-page":"2223","volume":"27","author":"Kirby","year":"1980"},{"key":"10.1016\/j.bbrc.2025.153155_bib15","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3390\/pharmaceutics17020276","article-title":"Navigating the clinical landscape of liposomal therapeutics in cancer treatment","volume":"17","author":"Kozak","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bbrc.2025.153155_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2020.113642","article-title":"Analytical characterization of liposomes and other lipid nanoparticles for drug delivery","volume":"192","author":"Fan","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.bbrc.2025.153155_bib17","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3390\/polym15020318","article-title":"Liposomes or extracellular vesicles: a comprehensive comparison of both lipid bilayer vesicles for pulmonary drug delivery","volume":"15","author":"Al-Jipouri","year":"2023","journal-title":"Polymers"},{"key":"10.1016\/j.bbrc.2025.153155_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e09394","article-title":"Liposomes: structure, composition, types, and clinical applications","volume":"8","author":"Nsairat","year":"2022","journal-title":"Heliyon"},{"key":"10.1016\/j.bbrc.2025.153155_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.120203","article-title":"Microfluidic production and characterization of biofunctionalized giant unilamellar vesicles for targeted intracellular cargo delivery","volume":"264","author":"Staufer","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.bbrc.2025.153155_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113851","article-title":"Liposome composition in drug delivery design, synthesis, characterization, and clinical application","volume":"176","author":"Large","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bbrc.2025.153155_bib21","unstructured":"S. Kline, Analysis of the fate of systemically administered liposomes and implications for their use in Drug Delivery, (n.d.)."},{"key":"10.1016\/j.bbrc.2025.153155_bib22","first-page":"17903","article-title":"Impact of lipid composition on vesicle protein adsorption: a BSA case study","volume":"9","author":"Am\u0103r\u0103ndi","year":"2024","journal-title":"Surf. Coat. Technol."},{"key":"10.1016\/j.bbrc.2025.153155_bib23","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1021\/acsnano.1c07687","article-title":"Opsonin-deficient nucleoproteic Corona endows UnPEGylated liposomes with stealth properties in vivo","volume":"16","author":"Giulimondi","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.bbrc.2025.153155_bib24","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S0618-8278(19)30829-1","article-title":"Super stealth immunoliposomes as a strategy to overcome liposome-induced liver toxicity","volume":"70","author":"Gabbia","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbrc.2025.153155_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202206968","article-title":"Biodegradable cationic and ionizable cationic lipids: a roadmap for safer pharmaceutical excipients","volume":"19","author":"J\u00f6rgensen","year":"2023","journal-title":"Small"},{"key":"10.1016\/j.bbrc.2025.153155_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100365","article-title":"Targeting immunoliposomes to EGFR-positive glioblastoma","volume":"7","author":"Kasenda","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.bbrc.2025.153155_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.eurpolymj.2022.111781","article-title":"Immunoliposomes as an emerging nanocarrier for breast cancer therapy","volume":"184","author":"Parveen","year":"2023","journal-title":"Eur. Polym. J."},{"key":"10.1016\/j.bbrc.2025.153155_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2025.102668","article-title":"Geometric-aware deep learning enables discovery of bifunctional ligand-based liposomes for tumor targeting therapy","volume":"61","author":"Xia","year":"2025","journal-title":"Nano Today"},{"key":"10.1016\/j.bbrc.2025.153155_bib29","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/17425247.2021.1828339","article-title":"Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery","volume":"18","author":"Majumder","year":"2021","journal-title":"Expet Opin. Drug Deliv."},{"key":"10.1016\/j.bbrc.2025.153155_bib30","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202303973","article-title":"Phosphorothioated DNA engineered liposomes as a general platform for stimuli-responsive cell-specific intracellular delivery and genome editing","volume":"62","author":"Yan","year":"2023","journal-title":"Angew. Chem."},{"key":"10.1016\/j.bbrc.2025.153155_bib31","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.jcis.2023.08.059","article-title":"Kinetic control of liposome size by direct lipid transfer","volume":"652","author":"Grosfils","year":"2023","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.bbrc.2025.153155_bib32","doi-asserted-by":"crossref","first-page":"R381","DOI":"10.1016\/j.cub.2018.01.086","article-title":"Membranes and evolution","volume":"28","author":"Gould","year":"2018","journal-title":"Curr. Biol."},{"key":"10.1016\/j.bbrc.2025.153155_bib33","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1080\/17425247.2022.2147505","article-title":"Study of FA12 peptide-modified PEGylated liposomal doxorubicin (PLD) as an effective ligand to target Muc1 in mice bearing C26 colon carcinoma: in silico, in vitro, and in vivo study","volume":"19","author":"Biabangard","year":"2022","journal-title":"Expet Opin. Drug Deliv."},{"key":"10.1016\/j.bbrc.2025.153155_bib34","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jconrel.2024.06.025","article-title":"Fine-tuning of liposome integrity for differentiated transcytosis and enhanced antitumor efficacy","volume":"372","author":"Su","year":"2024","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.bbrc.2025.153155_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124367","article-title":"Unravelling the interactions between small molecules and liposomal bilayers via molecular dynamics and thermodynamic modelling","volume":"660","author":"Miles","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.bbrc.2025.153155_bib36","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ijpharm.2010.01.003","article-title":"Physicochemical properties of extruded and non-extruded liposomes containing the hydrophobic drug dexamethasone","volume":"388","author":"Bhardwaj","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.bbrc.2025.153155_bib37","article-title":"A novel acoustic modulation of oscillating thin elastic membrane for enhanced streaming in microfluidics and nanoscale liposome production","volume":"20","author":"Vardin","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.bbrc.2025.153155_bib38","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1021\/acs.molpharmaceut.2c01078","article-title":"Computational prodrug design methodology for liposome formulability enhancement of small-molecule APIs","volume":"20","author":"Balouch","year":"2023","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bbrc.2025.153155_bib39","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: from concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv. Drug Deliv. Perspect. Prospects"},{"key":"10.1016\/j.bbrc.2025.153155_bib40","article-title":"Ethanol injection technique for liposomes formulation: an insight into development, influencing factors, challenges and applications","volume":"61","author":"Gouda","year":"2021","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.bbrc.2025.153155_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2023.1229829","article-title":"Evaluation of a static mixer as a new microfluidic method for liposome formulation","volume":"11","author":"Ota","year":"2023","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.bbrc.2025.153155_bib42","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41378-024-00815-0","article-title":"Facile and versatile PDMS-glass capillary double emulsion formation device coupled with rapid purification toward microfluidic giant liposome generation","volume":"10","author":"Bakouei","year":"2024","journal-title":"Microsyst. Nanoeng."},{"key":"10.1016\/j.bbrc.2025.153155_bib43","doi-asserted-by":"crossref","first-page":"23521","DOI":"10.1021\/acs.langmuir.4c03322","article-title":"Effect of solvent and cholesterol on liposome production by the reverse-phase evaporation (RPE) method","volume":"40","author":"Wehrle","year":"2024","journal-title":"Langmuir"},{"key":"10.1016\/j.bbrc.2025.153155_bib44","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11095-013-1135-z","article-title":"Freeze-Anneal-Thaw cycling of unilamellar liposomes: effect on encapsulation efficiency","volume":"31","author":"Costa","year":"2014","journal-title":"Pharm. Res."},{"key":"10.1016\/j.bbrc.2025.153155_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/527516","article-title":"Combination drug delivery approaches in metastatic breast cancer","volume":"2012","author":"Lee","year":"2012","journal-title":"J. Drug Deliv."},{"key":"10.1016\/j.bbrc.2025.153155_bib46","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.2147\/IJN.S488961","article-title":"Advancements in liposomal nanomedicines: innovative formulations, therapeutic applications, and future directions in precision medicine","volume":"20","author":"Izadiyan","year":"2025","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.bbrc.2025.153155_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124884","article-title":"Novel microfluidic development of pH-responsive hybrid liposomes: in vitro and in vivo assessment for enhanced wound healing","volume":"667","author":"Alaqabani","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.bbrc.2025.153155_bib48","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.2147\/IJN.S303874","article-title":"A dual pH-Responsive DOX-encapsulated liposome combined with glucose administration enhanced therapeutic efficacy of chemotherapy for cancer","volume":"16","author":"Zhai","year":"2021","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.bbrc.2025.153155_bib49","doi-asserted-by":"crossref","first-page":"16711","DOI":"10.1073\/pnas.1903500116","article-title":"Building a synthetic mechanosensitive signaling pathway in compartmentalized artificial cells","volume":"116","author":"Hindley","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbrc.2025.153155_bib50","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0005-2736(79)90085-3","article-title":"Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes","volume":"557","author":"Olson","year":"1979","journal-title":"Biochim. Biophys. Acta BBA - Biomembr."},{"key":"10.1016\/j.bbrc.2025.153155_bib51","series-title":"Trends Colloid Interface Sci. VI","first-page":"127","article-title":"Preparation of giant vesicles by external AC electric fields. Kinetics and applications","author":"Angelova","year":"1992"},{"key":"10.1016\/j.bbrc.2025.153155_bib52","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/s41467-018-03491-7","article-title":"Light-triggered enzymatic reactions in nested vesicle reactors","volume":"9","author":"Hindley","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2025.153155_bib53","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1080\/08982104.2023.2226216","article-title":"Liposome bilayer stability: emphasis on cholesterol and its alternatives","volume":"34","author":"Nsairat","year":"2024","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.bbrc.2025.153155_bib54","first-page":"142","article-title":"Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers. Adv. Drug deliv. 2020 - part 2 routes deliv","volume":"157","author":"Fang","year":"2020","journal-title":"Biol. Barriers"},{"key":"10.1016\/j.bbrc.2025.153155_bib55","doi-asserted-by":"crossref","first-page":"7921","DOI":"10.7150\/thno.49577","article-title":"The EPR effect and beyond: strategies to improve tumor targeting and cancer nanomedicine treatment efficacy","volume":"10","author":"Shi","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.bbrc.2025.153155_bib56","doi-asserted-by":"crossref","first-page":"8373","DOI":"10.2147\/IJN.S472433","article-title":"Chitosan nanoparticles for targeted cancer therapy: a review of stimuli-responsive, passive, and active targeting strategies","volume":"19","author":"Al-Shadidi","year":"2024","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.bbrc.2025.153155_bib57","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jconrel.2021.01.021","article-title":"Ultra-small lipid nanoparticles encapsulating sorafenib and Midkine-siRNA selectively-eradicate sorafenib-resistant hepatocellular carcinoma in vivo","volume":"331","author":"Younis","year":"2021","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.bbrc.2025.153155_bib58","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ijpharm.2017.11.031","article-title":"Polymer-based nanoparticles loaded with a TLR7 ligand to target the lymph node for immunostimulation","volume":"535","author":"Widmer","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.bbrc.2025.153155_bib59","article-title":"From bench to bedside: advancing liposomal doxorubicin for targeted cancer therapy","volume":"19","author":"Ahmad","year":"2025","journal-title":"Results Surf. Interfaces"},{"key":"10.1016\/j.bbrc.2025.153155_bib60","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/0140-6736(93)91147-E","article-title":"Liposomal daunorubicin treatment of HIV-associated kaposi's sarcoma","volume":"341","author":"Presant","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.bbrc.2025.153155_bib61","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1093\/annonc\/mdi209","article-title":"Phase I trial of liposomal encapsulated doxorubicin (MyocetTM; D-99) and weekly docetaxel in advanced breast cancer patients","volume":"16","author":"Mr\u00f3zek","year":"2005","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbrc.2025.153155_bib62","unstructured":"Drugs@FDA: FDA-approved drugs, (n.d.). https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=BasicSearch.process (accessed November 15, 2025)."},{"key":"10.1016\/j.bbrc.2025.153155_bib63","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41392-019-0068-3","article-title":"Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles","volume":"4","author":"Singh","year":"2019","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.bbrc.2025.153155_bib64","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.biochi.2024.07.017","article-title":"Tailor-made vincristine-liposomes for tumor targeting","volume":"227","author":"Abawi","year":"2024","journal-title":"Biochimie"},{"key":"10.1016\/j.bbrc.2025.153155_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104386","article-title":"Safety and efficacy of liposomal irinotecan as the second-line treatment for advanced pancreatic cancer: a systematic review and meta-analysis","volume":"201","author":"Chen","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.bbrc.2025.153155_bib66","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (Cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2025.153155_bib67","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.addr.2020.05.013","article-title":"Three significant highlights of controlled drug delivery over the past 55 years: pegylation, ADCs, and EPR","volume":"158","author":"Hoffman","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bbrc.2025.153155_bib68","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241612827","article-title":"Nanoparticles in medicine: current status in cancer treatment","volume":"24","author":"Paveli\u0107","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2025.153155_bib69","first-page":"154","article-title":"Liposomes: advancements and innovation in the manufacturing process","author":"Shah","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bbrc.2025.153155_bib70","article-title":"Synergistic strategies for enhanced liver cancer therapy with sorafenib\/resveratrol PEGylated liposomes in vitro and in vivo","volume":"96","author":"Alrashidi","year":"2024","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.bbrc.2025.153155_bib71","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15507","article-title":"Conditional internalization of PEGylated nanomedicines by PEG engagers for triple negative breast cancer therapy","volume":"8","author":"Su","year":"2017","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.bbrc.2025.153155_bib72","doi-asserted-by":"crossref","first-page":"14022","DOI":"10.1021\/acsnano.1c05922","article-title":"Polyethylene glycol immunogenicity: theoretical, clinical, and practical aspects of anti-polyethylene glycol antibodies","volume":"15","author":"Chen","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.bbrc.2025.153155_bib73","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202409635","article-title":"Antibody\u2010nanoparticle conjugates in therapy: combining the best of two worlds","volume":"21","author":"Adhikari","year":"2025","journal-title":"Small"},{"key":"10.1016\/j.bbrc.2025.153155_bib74","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jconrel.2023.02.004","article-title":"Regulation of protein Corona on liposomes using albumin-binding peptide for targeted tumor therapy","volume":"355","author":"Li","year":"2023","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"10.1016\/j.bbrc.2025.153155_bib75","doi-asserted-by":"crossref","first-page":"13685","DOI":"10.1021\/acsnano.4c14625","article-title":"Peptide-modified lipid nanoparticles boost the antitumor efficacy of RNA therapeutics","volume":"19","author":"Zhao","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.bbrc.2025.153155_bib76","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.jconrel.2022.10.016","article-title":"Cationic lipid potentiated the adjuvanticity of polysaccharide derivative-modified liposome vaccines","volume":"362","author":"Yuba","year":"2023","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.bbrc.2025.153155_bib77","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41577-024-01026-4","article-title":"Cancer cell metabolism and antitumour immunity","volume":"24","author":"Martino","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbrc.2025.153155_bib78","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13045-024-01574-1","article-title":"Lipid-based nanosystems: the next generation of cancer immune therapy","volume":"17","author":"Cheng","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bbrc.2025.153155_bib79","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1073\/pnas.83.8.2699","article-title":"Immune clearance of liposomes inhibited by an Anti-Fc receptor antibody in vivo","volume":"83","author":"Aragnol","year":"1986","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bbrc.2025.153155_bib80","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/0005-2736(94)00263-O","article-title":"Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol) s conjugated at their distal terminals to monoclonal antibodies","volume":"1234","author":"Maruyama","year":"1995","journal-title":"Biochim. Biophys. Acta BBA - Biomembr."},{"key":"10.1016\/j.bbrc.2025.153155_bib81","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0014-5793(97)00905-8","article-title":"Immunoliposomes bearing polyethyleneglycol\u2010coupled fab' fragment show prolonged circulation time and high extravasation into targeted solid tumors in vivo","volume":"413","author":"Maruyama","year":"1997","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bbrc.2025.153155_bib82","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noae064.335","article-title":"HGG-51. Intranasal delivery of PDGFRA-immunoliposomal SN-38 for the treatment of pediatric high-grade gliomas","volume":"26","author":"Kaur","year":"2024","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.bbrc.2025.153155_bib83","first-page":"1172","article-title":"Anti-HER2 immunoliposomes : enhanced efficacy attributable to targeted delivery","volume":"8","author":"Park","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2025.153155_bib84","doi-asserted-by":"crossref","DOI":"10.1038\/s41585-024-00958-9","article-title":"Immunoliposome targeting IL-30","volume":"21","author":"Lloyd","year":"2024","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.bbrc.2025.153155_bib85","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12951-021-00846-z","article-title":"Dual activity of PD-L1 targeted doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model","volume":"19","author":"Merino","year":"2021","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.bbrc.2025.153155_bib86","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbrc.2025.153155_bib87","doi-asserted-by":"crossref","first-page":"9825","DOI":"10.1021\/acs.nanolett.5c02262","article-title":"Impact of renal-targeting ligand density on kidney targeting, clearance, and off-target effects of renal-clearable nanoparticles","volume":"25","author":"Song","year":"2025","journal-title":"Nano Lett."},{"key":"10.1016\/j.bbrc.2025.153155_bib88","doi-asserted-by":"crossref","first-page":"6886","DOI":"10.1021\/acsnano.2c02084","article-title":"Quantification of available ligand density on the surface of targeted liposomal nanomedicines at the single-particle level","volume":"16","author":"Chen","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.bbrc.2025.153155_bib89","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.3390\/pharmaceutics15102385","article-title":"Folate-targeted nanoliposomal chemophototherapy","volume":"15","author":"Chitgupi","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bbrc.2025.153155_bib90","first-page":"191","article-title":"Surface modification of liposomes using folic acid","volume":"2622","author":"Guo","year":"2023"},{"key":"10.1016\/j.bbrc.2025.153155_bib91","first-page":"42","article-title":"Research progress of antibody\u2013drug conjugates in gynecologic cancer. Holist. Integr","volume":"3","author":"Xu","year":"2024","journal-title":"Oncol"},{"key":"10.1016\/j.bbrc.2025.153155_bib92","first-page":"2135","article-title":"Folate receptor-mediated drug targeting: from therapeutics to diagnostics","volume":"94","author":"Hilgenbrink","year":"2005","journal-title":"J. Pharm. (Lahore)"},{"key":"10.1016\/j.bbrc.2025.153155_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106287","article-title":"Quercetin encapsulated in folic acid-modified liposomes is therapeutic against osteosarcoma by non-covalent binding to the JH2 domain of JAK2 via the JAK2-STAT3-PDL1","volume":"182","author":"Jing","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bbrc.2025.153155_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117192","article-title":"Targeted Co-Delivery of rapamycin and oxaliplatin by liposomes suppresses tumor growth and metastasis of colorectal cancer","volume":"178","author":"Yu","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbrc.2025.153155_bib95","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41392-020-0115-0","article-title":"Targeting folate receptor \u03b2 positive tumor-associated macrophages in lung cancer with a folate-modified liposomal complex","volume":"5","author":"Tie","year":"2020","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.bbrc.2025.153155_bib96","first-page":"1949","article-title":"Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump","volume":"6","author":"Goren","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2025.153155_bib97","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jconrel.2025.01.060","article-title":"Receptor-ligand interactions for optimized endocytosis in targeted therapies","volume":"380","author":"Sung","year":"2025","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.bbrc.2025.153155_bib98","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1080\/10837450.2020.1786116","article-title":"Transferrin receptors targeting peptide (T7 peptide) surface-modified sorafenib nanoliposomes enhance the anti-tumor effect in colorectal cancer","volume":"25","author":"Wang","year":"2020","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.bbrc.2025.153155_bib99","article-title":"Transferrin conjugated stealth liposomes for sirolimus active targeting in breast cancer","volume":"66","author":"Nandi","year":"2021","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.bbrc.2025.153155_bib100","article-title":"Transferrin-functionalized liposomes for docetaxel delivery to prostate cancer cells","volume":"611","author":"Fernandes","year":"2021","journal-title":"Colloids Surf. A Physicochem. Eng. Asp."},{"key":"10.1016\/j.bbrc.2025.153155_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2024.153371","article-title":"Self-enhanced targeted nanomedicines based on iron starvation acclimation for tumor-specific therapy","volume":"495","author":"Guan","year":"2024","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.bbrc.2025.153155_bib102","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s12951-021-01048-3","article-title":"Active targeting of orthotopic glioma using biomimetic liposomes Co-Loaded elemene and cabazitaxel modified by transferritin","volume":"19","author":"Li","year":"2021","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.bbrc.2025.153155_bib103","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202200353","article-title":"Functionalized macrophage exosomes with panobinostat and PPM1D\u2010siRNA for diffuse intrinsic pontine gliomas therapy","volume":"9","author":"Shan","year":"2022","journal-title":"Adv. Sci."},{"key":"10.1016\/j.bbrc.2025.153155_bib104","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1186\/s12951-025-03528-2","article-title":"Exosomes as nanocarriers for brain-targeted delivery of therapeutic nucleic acids: advances and challenges","volume":"23","author":"Sanadgol","year":"2025","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.bbrc.2025.153155_bib105","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1021\/acsnano.0c09382","article-title":"Hybrid nanosystems for biomedical applications","volume":"15","author":"Seaberg","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.bbrc.2025.153155_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114635","article-title":"Protein corona: friend or foe? Co-opting serum proteins for nanoparticle delivery","volume":"192","author":"Kim","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bbrc.2025.153155_bib107","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.actbio.2021.07.074","article-title":"Spotlight on the protein corona of liposomes","volume":"134","author":"Onishchenko","year":"2021","journal-title":"Acta Biomater."},{"key":"10.1016\/j.bbrc.2025.153155_bib108","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.767","article-title":"Nanomedicine for cancer patient\u2010centered care","volume":"5","author":"Sorrentino","year":"2024","journal-title":"MedComm"},{"key":"10.1016\/j.bbrc.2025.153155_bib109","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/mt.2010.85","article-title":"Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms","volume":"18","author":"Akinc","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bbrc.2025.153155_bib110","doi-asserted-by":"crossref","first-page":"10731","DOI":"10.1039\/C8NR03331E","article-title":"Exploiting the biomolecular corona: pre-coating of nanoparticles enables controlled cellular interactions","volume":"10","author":"Simon","year":"2018","journal-title":"Nanoscale"},{"key":"10.1016\/j.bbrc.2025.153155_bib111","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1186\/s12951-025-03565-x","article-title":"Engineered protein corona sustains stealth functionality of nanocarriers in plasma","volume":"23","author":"Zhang","year":"2025","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.bbrc.2025.153155_bib112","first-page":"2688","article-title":"Poly(l-glutamic acid)-cisplatin nanoformulations with detachable PEGylation for prolonged circulation half-life and enhanced cell internalization","volume":"6","author":"Jiang","year":"2021","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.bbrc.2025.153155_bib113","doi-asserted-by":"crossref","first-page":"4716","DOI":"10.3390\/ijms22094716","article-title":"Hexokinase 2 in cancer: a prima donna playing multiple characters","volume":"22","author":"Ciscato","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2025.153155_bib114","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1080\/10717544.2018.1458920","article-title":"Estrogen-functionalized liposomes grafted with glutathione-responsive sheddable chotooligosaccharides for the therapy of osteosarcoma","volume":"25","author":"Yin","year":"2018","journal-title":"Drug Deliv."},{"key":"10.1016\/j.bbrc.2025.153155_bib115","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1158\/1535-7163.MCT-23-0099","article-title":"FF-10850, a novel liposomal topotecan achieves superior antitumor activity via Macrophage- and ammonia-mediated payload release in the tumor microenvironment","volume":"22","author":"Shimoyama","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbrc.2025.153155_bib116","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.3097","article-title":"A phase 1, First-in-Human, dose-escalation and biomarker trial of liposomal gemcitabine (FF-10832) in patients with advanced solid tumors","volume":"40","author":"Borazanci","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2025.153155_bib117","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.2615","article-title":"A phase 2a safety Run-in and preliminary efficacy study of liposomal gemcitabine (FF-10832) in combination with pembrolizumab in patients with advanced solid tumors","volume":"42","author":"Langer","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2025.153155_bib118","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/s41416-018-0235-2","article-title":"Safety and pharmacokinetics of MM-302, a HER2-targeted antibody\u2013liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study","volume":"119","author":"Munster","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbrc.2025.153155_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100212","article-title":"Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study)","volume":"6","author":"Perez-Fidalgo","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.bbrc.2025.153155_bib120","article-title":"GEICO1601-ROLANDO: a multicentric single arm phase II clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer","volume":"5","author":"Perez-Fidalgo","year":"2019","journal-title":"Future Sci."},{"key":"10.1016\/j.bbrc.2025.153155_bib121","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ygyno.2020.07.028","article-title":"Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: a phase 2 clinical trial","volume":"159","author":"Lee","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.bbrc.2025.153155_bib122","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","article-title":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial","volume":"15","author":"Judson","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbrc.2025.153155_bib123","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbrc.2025.153155_bib124","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S2352-3026(18)30192-3","article-title":"Safety and activity of sintilimab in patients with relapsed or refractory classical hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial","volume":"6","author":"Shi","year":"2019","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.bbrc.2025.153155_bib125","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1703643","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-Positive breast cancer","volume":"377","author":"Minckwitz","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"2014","key":"10.1016\/j.bbrc.2025.153155_bib126","first-page":"9","article-title":"Cancer statistics","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bbrc.2025.153155_bib127","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1634\/theoncologist.2009-0029","article-title":"Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational hermine study","volume":"15","author":"Extra","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.bbrc.2025.153155_bib128","first-page":"1488","article-title":"Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases","volume":"43","author":"Fisher","year":"1983","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2025.153155_bib129","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/S1470-2045(17)30717-9","article-title":"Neratinib after trastuzumab-based adjuvant therapy in HER2-Positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"18","author":"Martin","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbrc.2025.153155_bib130","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1093\/annonc\/mdr024","article-title":"Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-Positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM\/2004\u201305 study","volume":"22","author":"Mart\u00edn","year":"2011","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbrc.2025.153155_bib131","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)","volume":"24","author":"Schneeweiss","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbrc.2025.153155_bib132","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","article-title":"CLEOPATRA study group, ciruelos, pertuzumab, trastuzumab, and docetaxel for HER2-Positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study","volume":"21","author":"Swain","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbrc.2025.153155_bib133","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S1470-2045(17)30312-1","article-title":"Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-Positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial","volume":"18","author":"Di\u00e9ras","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbrc.2025.153155_bib134","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3390\/cells10020246","article-title":"Cytokine-coding oncolytic adenovirus TILT-123 is safe, selective, and effective as a single agent and in combination with immune checkpoint inhibitor Anti-PD-1","volume":"10","author":"Havunen","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.bbrc.2025.153155_bib135","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2022.06.058","article-title":"Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: a network metanalysis of phase III trials","volume":"174","author":"Fulgenzi","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bbrc.2025.153155_bib136","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-034527","volume":"10","author":"Craig","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.bbrc.2025.153155_bib137","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"Groupe tumeurs digestives of unicancer; PRODIGE intergroup, FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Thierry","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrc.2025.153155_bib138","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.4143\/crt.2017.526","article-title":"Multicenter phase II study of oxaliplatin, irinotecan, and S-1 as first-line treatment for patients with recurrent or metastatic biliary tract cancer","volume":"50","author":"Yoo","year":"2018","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.bbrc.2025.153155_bib139","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","article-title":"NAPOLI-1 study group, nanoliposomal Irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial","volume":"387","author":"Wang-Gillam","year":"2016","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.bbrc.2025.153155_bib140","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1200\/JCO.2002.07.116","article-title":"Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia","volume":"20","author":"Linker","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2025.153155_bib141","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3324\/haematol.2010.028092","volume":"96","author":"Gokbuget","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.bbrc.2025.153155_bib142","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1038\/s41375-021-01256-8","article-title":"A dose substitution of anthracycline intensity with dose-dense rituximab in children and adolescents with good-risk mature B-cell lymphoma","volume":"35","author":"Goldman","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrc.2025.153155_bib143","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.addr.2020.06.005","article-title":"Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers","volume":"157","author":"Fang","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bbrc.2025.153155_bib144","doi-asserted-by":"crossref","DOI":"10.1038\/natrevmats.2016.14","article-title":"Analysis of nanoparticle delivery to tumours","volume":"1","author":"Wilhelm","year":"2016","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.bbrc.2025.153155_bib145","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1158\/1535-7163.MCT-24-0024","article-title":"PET imaging using 89Zr-Labeled StarPEG nanocarriers reveals heterogeneous enhanced permeability and retention in prostate cancer","volume":"24","author":"Meher","year":"2025","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbrc.2025.153155_bib146","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202103745","article-title":"Monitoring EPR effect dynamics during nanotaxane treatment with theranostic polymeric micelles","volume":"9","author":"Biancacci","year":"2022","journal-title":"Adv. Sci."},{"key":"10.1016\/j.bbrc.2025.153155_bib147","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/nrc1456","article-title":"High interstitial fluid pressure \u2014 an obstacle in cancer therapy","volume":"4","author":"Heldin","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbrc.2025.153155_bib148","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114614","article-title":"The tumor EPR effect for cancer drug delivery: current status, limitations, and alternatives","volume":"191","author":"Sun","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bbrc.2025.153155_bib149","doi-asserted-by":"crossref","first-page":"32045","DOI":"10.1021\/acsnano.4c10381","article-title":"Extracellular matrix limits nanoparticle diffusion and cellular uptake in a tissue-specific manner","volume":"18","author":"Cahn","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.bbrc.2025.153155_bib150","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41563-019-0566-2","article-title":"The entry of nanoparticles into solid tumours","volume":"19","author":"Sindhwani","year":"2020","journal-title":"Nat. Mater."},{"key":"10.1016\/j.bbrc.2025.153155_bib151","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.111103","article-title":"Nanomedicines: redefining traditional medicine","volume":"134","author":"Lu","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbrc.2025.153155_bib152","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3390\/molecules23020288","article-title":"Liposomes: clinical applications and potential for image-guided drug delivery","volume":"23","author":"Lamichhane","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.bbrc.2025.153155_bib153","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1186\/s12885-016-2385-z","article-title":"HERMIONE: a randomized phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-na\u00efve, HER2-positive, locally advanced\/metastatic breast cancer","volume":"16","author":"Miller","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bbrc.2025.153155_bib154","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10246","article-title":"Nanoparticles in the clinic: an update post COVID\u201019 vaccines","volume":"6","author":"Anselmo","year":"2021","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.bbrc.2025.153155_bib155","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1021\/acsnano.9b08142","article-title":"Meta-analysis of nanoparticle delivery to tumors using a physiologically based pharmacokinetic modeling and simulation approach","volume":"14","author":"Cheng","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.bbrc.2025.153155_bib156","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202211420","article-title":"Optimizing lipid nanoparticles for delivery in Primates","volume":"35","author":"Lam","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.bbrc.2025.153155_bib157","first-page":"751","article-title":"Physical and chemical properties of nano-liposome, application in nano medicine","volume":"52","author":"Eskandari","year":"2021","journal-title":"J. Comput. Appl. Mech."},{"key":"10.1016\/j.bbrc.2025.153155_bib158","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2025.159552","article-title":"Emerging mechanistic insights into liposomal stability: full process management from production and storage to food application","volume":"505","author":"Xu","year":"2025","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.bbrc.2025.153155_bib159","doi-asserted-by":"crossref","DOI":"10.1016\/j.foodchem.2023.135517","article-title":"Glycolipids improve the stability of liposomes: the perspective of bilayer membrane structure","volume":"412","author":"Yi","year":"2023","journal-title":"Food Chem."},{"key":"10.1016\/j.bbrc.2025.153155_bib160","article-title":"Novel 3D integrated microfluidic device: design, construction, and application to the preparation of liposomes for vaccine delivery","volume":"91","author":"Xiu","year":"2024","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.bbrc.2025.153155_bib161","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.3390\/molecules27041372","article-title":"A review of liposomes as a drug delivery system: current status of approved products, regulatory environments,and future perspectives","volume":"27","author":"Liu","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.bbrc.2025.153155_bib162","first-page":"2898","article-title":"Efficacy and safety profile of CPX-351 in secondary Acute Myeloid Leukemia (sAML): a systematic review, 65th ASH annu. Meet","volume":"142","author":"Ibrahim","year":"2023","journal-title":"Abstr"},{"key":"10.1016\/j.bbrc.2025.153155_bib163","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113985","article-title":"Drug development of lyso-thermosensitive liposomal doxorubicin: combining hyperthermia and thermosensitive drug delivery","volume":"178","author":"Borys","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bbrc.2025.153155_bib164","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jconrel.2017.01.025","article-title":"To heat or not to heat: challenges with clinical translation of thermosensitive liposomes","volume":"249","author":"Dou","year":"2017","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.bbrc.2025.153155_bib165","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYXTM\/Doxil\u00ae) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer","volume":"15","author":"O'Brien","year":"2004","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbrc.2025.153155_bib166","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1023\/A:1008365716693","article-title":"Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg\/m2","volume":"11","author":"Safra","year":"2000","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.bbrc.2025.153155_bib167","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.2147\/IJN.S139450","article-title":"CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties","volume":"14","author":"Mayer","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.bbrc.2025.153155_bib168","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1016\/S2352-3026(21)00134-4","article-title":"CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial","volume":"8","author":"Lancet","year":"2021","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.bbrc.2025.153155_bib169","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1038\/s41467-023-40312-y","article-title":"Chemically programmed STING-activating nano-liposomal vesicles improve anticancer immunity","volume":"14","author":"Chen","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2025.153155_bib170","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jconrel.2021.12.023","article-title":"Paclitaxel derivative-based liposomal nanoplatform for potentiated chemo-immunotherapy","volume":"341","author":"Wang","year":"2022","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"10.1016\/j.bbrc.2025.153155_bib171","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3390\/pharmaceutics14020458","article-title":"Increased targeting area in tumors by dual-ligand modification of liposomes with RGD and TAT peptides","volume":"14","author":"Amin","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bbrc.2025.153155_bib172","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.actbio.2020.04.029","article-title":"Bispecific antibody (HER2 \u00d7 mPEG) enhances anti-cancer effects by precise targeting and accumulation of mPEGylated liposomes","volume":"111","author":"Chen","year":"2020","journal-title":"Acta Biomater."},{"key":"10.1016\/j.bbrc.2025.153155_bib173","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1186\/s12951-024-02870-1","article-title":"Targeted blood-brain barrier penetration and precise imaging of infiltrative glioblastoma margins using hybrid cell membrane-coated ICG liposomes","volume":"22","author":"Liu","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.bbrc.2025.153155_bib174","doi-asserted-by":"crossref","first-page":"7928","DOI":"10.1021\/acsnano.4c14969","article-title":"siRNA-Encapsulated biomimetic liposomes effectively inhibit tumor cells' hexosamine biosynthesis pathway for attenuating hyaluronan barriers to pancreatic cancer chemotherapy","volume":"19","author":"Wu","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.bbrc.2025.153155_bib175","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114416","article-title":"The role of lipid components in lipid nanoparticles for vaccines and gene therapy","volume":"188","author":"Hald Albertsen","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bbrc.2025.153155_bib176","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature18300","article-title":"Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy","volume":"534","author":"Kranz","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2025.153155_bib177","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2025.153155_bib178","article-title":"Supramolecular lipid nanoparticles based on host-guest recognition: a new generation delivery system of mRNA vaccines for cancer immunotherapy","volume":"36","author":"Qi","year":"2024","journal-title":"Adv. Mater. Deerfield Beach Fla"},{"key":"10.1016\/j.bbrc.2025.153155_bib179","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2025.153155_bib180","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.apsb.2023.10.012","article-title":"Lipid nanovehicles overcome barriers to systemic RNA delivery: lipid components, fabrication methods, and rational design","volume":"14","author":"Yan","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bbrc.2025.153155_bib181","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","article-title":"mRNA vaccines for infectious diseases: principles, delivery and clinical translation","volume":"20","author":"Chaudhary","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbrc.2025.153155_bib182","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.ymthe.2004.12.018","article-title":"Nonbilayer phase of lipoplex\u2013membrane mixture determines endosomal escape of genetic cargo and transfection efficiency","volume":"11","author":"Zuhorn","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bbrc.2025.153155_bib183","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/j.bbamem.2016.04.014","article-title":"Lipid rafts-mediated endocytosis and physiology-based cell membrane traffic models of doxorubicin liposomes","volume":"1858","author":"Li","year":"2016","journal-title":"Biochim. Biophys. Acta BBA - Biomembr."},{"key":"10.1016\/j.bbrc.2025.153155_bib184","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40265-016-0538-7","article-title":"Liposomal amphotericin B (AmBisome\u00ae): a review of the pharmacokinetics, pharmacodynamics, clinical experience and future directions","volume":"76","author":"Stone","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.bbrc.2025.153155_bib185","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1021\/acs.accounts.1c00544","article-title":"Chemistry of lipid nanoparticles for RNA delivery","volume":"55","author":"Eygeris","year":"2022","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.bbrc.2025.153155_bib186","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1038\/s41551-024-01267-7","article-title":"Optimization of the activity and biodegradability of ionizable lipids for mRNA delivery via directed chemical evolution","volume":"8","author":"Han","year":"2024","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.bbrc.2025.153155_bib187","article-title":"Comprehensive analysis of lipid nanoparticle formulation and preparation for RNA delivery","volume":"X 8","author":"Haque","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.bbrc.2025.153155_bib188","doi-asserted-by":"crossref","first-page":"7509","DOI":"10.7150\/thno.77259","article-title":"Lipid nanoparticles for delivery of RNA therapeutics: current status and the role of in vivo imaging","volume":"12","author":"Jung","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.bbrc.2025.153155_bib189","doi-asserted-by":"crossref","first-page":"13147","DOI":"10.1021\/acsnano.2c11904","article-title":"Insights into the structure of comirnaty Covid-19 vaccine: a theory on soft, partially bilayer-covered nanoparticles with hydrogen bond-stabilized mRNA\u2013Lipid complexes","volume":"17","author":"Szebeni","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.bbrc.2025.153155_bib190","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1038\/s12276-023-01086-x","article-title":"Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics","volume":"55","author":"Lee","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.bbrc.2025.153155_bib191","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202206968","article-title":"Biodegradable cationic and ionizable cationic lipids: a roadmap for safer pharmaceutical excipients","volume":"19","author":"J\u00f6rgensen","year":"2023","journal-title":"Small"},{"key":"10.1016\/j.bbrc.2025.153155_bib192","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1474-4422(20)30368-9","article-title":"Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study","volume":"20","author":"Adams","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.bbrc.2025.153155_bib193","doi-asserted-by":"crossref","first-page":"21733","DOI":"10.1039\/C9NR09347H","article-title":"On the role of helper lipids in lipid nanoparticle formulations of siRNA","volume":"11","author":"Kulkarni","year":"2019","journal-title":"Nanoscale"},{"key":"10.1016\/j.bbrc.2025.153155_bib194","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1016\/j.cell.2022.03.045","article-title":"Therapeutic in vivo delivery of gene editing agents","volume":"185","author":"Raguram","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2025.153155_bib195","article-title":"A phase I study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36\u03b3, for intratumoral (iTu) injection alone and in combination with durvalumab","volume":"38","author":"Patel","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2025.153155_bib196","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jconrel.2011.06.001","article-title":"Targeted drug delivery to tumors: myths, reality and possibility","volume":"153","author":"Bae","year":"2011","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.bbrc.2025.153155_bib197","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1038\/s41563-024-02114-5","article-title":"Blood\u2013brain-barrier-crossing lipid nanoparticles for mRNA delivery to the central nervous system","volume":"24","author":"Wang","year":"2025","journal-title":"Nat. Mater."},{"key":"10.1016\/j.bbrc.2025.153155_bib198","article-title":"Application of novel drug\u2010delivery strategies in neurological disorders","volume":"37","author":"Li","year":"2025","journal-title":"Adv. Mater."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X25018716?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X25018716?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T04:29:34Z","timestamp":1768451374000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X25018716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":198,"alternative-id":["S0006291X25018716"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2025.153155","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting strategies, clinical translation and translational barriers of liposomes in cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2025.153155","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"153155"}}